No profile data available.
Kyverna Therapeutics, Inc. (KYTX) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in EmeryVille, United States, with about 149 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$161.31 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $395.18 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Kyverna Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$395.18 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Monte Rosa Therapeutics, Inc. (GLUE), Climb Bio Inc (CLYM), Shattuck Labs, Inc. (STTK), Zura Bio Limited (ZURA).